Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

INCLUSION CRITERIA: DISEASE CHARACTERISTICS: * Confirmed diagnosis of hairy cell leukemia * Measurable disease At least one of the following indications for treatment: * Neutropenia (ANC \<1000 cells/µL) * Anemia (Hgb \<10g/dL) * Thrombocytopenia (Plt \<100,000/µL) * An absolute lymphocyte count of \>20,000 cells/µL, or * Symptomatic splenomegaly * Patient's must have had at least 2 prior systemic therapies. There must have been at least 2 prior courses of purine analog, or 1 if the response to this course lasted \<2 years, or if the patient had unacceptable toxicity to purine analog. PATIENT CHARACTERISTICS: Performance status • ECOG 0-2 Life expectancy • Life expectancy of greater than 6 months, as assessed by the principal investigator Other * Patients with other cancers who meet eligibility criteria and have had less than 5 years of disease free survival will be considered on a case-by-case basis * Ability to understand and sign informed consent * Female and male patients agree to use an approved method of contraception during the study EXCLUSION CRITERIA: * Documented and ongoing central nervous system involvement with their malignant disease (history of CNS involvement is not an exclusion criterion) * History of bone marrow transplant * Pregnant or breast-feeding females * Patients whose plasma contains either a significant level of antibody to CAT-8015 as measured by ELISA, or antibody that neutralizes the binding of CAT-8015 to CD22 as measured by a competition ELISA. * HIV positive serology (due to increased risk of severe infection and unknown interaction of CAT-8015 with antiretroviral drugs) * Hepatitis B surface antigen positive * Uncontrolled, symptomatic, intercurrent illness including but not limited to: infections requiring systemic antibiotics, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements Hepatic function: serum transaminases (either ALT or AST) or bilirubin: • ≥ Grade 2, unless bilirubin is due to Gilbert's disease Renal function: serum creatinine clearance ≤60mL/min as estimated by Cockroft-Gault formula Hematologic function: * The ANC \<1000/cmm, or platelet count \<50,000/cmm, if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy) * Baseline coagulopathy \> grade 3 unless due to anticoagulant therapy * A patient will not be excluded because of pancytopenia ≥ Grade 3, or erythropoietin dependence, if it is due to disease, based on the results of bone marrow studies Pulmonary function: • Patients with \< 50% of predicted forced expiratory volume (FEV1) or \<50% of predicted diffusing capacity for carbon monoxide (DLCO), corrected for hemoglobin concentration and alveolar volume. Note: Patients with no prior history of pulmonary illness are not required to have PFTs. FEV1 will be assessed following bronchodilator therapy. Recent prior therapy: * Cytotoxic chemotherapy (except stable doses of prednisone), whole body electron beam radiation therapy, interferon, retinoids or other systemic therapy, or investigational therapy of the malignancy for 3 weeks prior to entry into the trial * Less than or equal to \< 3 months prior monoclonal antibody therapy (i.e. rituximab) * Patients who have received or are receiving radiation therapy less than 3 weeks prior to study entry will be not be excluded providing the volume of bone marrow treated is less than 10% and also the patient has measurable disease outside the radiation port * Any history of pseudomonas-exotoxin (PE) immunotoxin administration